News

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...
Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...
Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.
The US Food and Drug Administration (FDA) has granted approval for a label update to Eli Lilly and Company's Amyvid ...
The label update for Amyvid adds guidance for assessing amyloid plaque levels and may help inform diagnostic and treatment ...
Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...
Eli Lilly and Company (NYSE: LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli ...
Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging ...